Lupus Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2032
Overview
The Lupus Market size was valued at USD 3.01 Billion in 2024 and the total Lupus revenue is expected to grow at a CAGR of 12.41% from 2025 to 2032, reaching nearly USD 7.68 Billion.
Lupus Market Overview:
The global lupus market was valued at USD 3.01 Bn. in 2024. Lupus is a chronic autoimmune disease that causes inflammation all over the body. In patients with lupus, the immune system attacks its own tissues and can damage several parts of the body including kidney, heart, skin, joints, lungs, brain, and blood vessels. Lupus patients may be at higher risk of developing severe infections if they develop COVID-19.
To know about the Research Methodology :- Request Free Sample Report
Lupus Market Dynamics:
The market for lupus is growing at breakneck speed across the world because of the surging prevalence of lupus and the ongoing medical developments in treating systemic lupus erythematous. The increased R&D activities for lupus can be considered a driving factor. Throughout the world, approximately 5 million people suffer from lupus and 70% of the total cases are systemic lupus erythematous. As per the Lupus Foundation of America, approximately 1.5 million Americans have a form of lupus, and around 16,000 new cases are reported yearly in the Americans. However, stringent regulatory guidelines for new drugs and the cost restraint are expected to be among the primary hindrance. Likewise, the MMR report covers all the trends and technologies playing a major role in the growth of the lupus market over the 2025-2032. It highlights the drivers, restraints, and opportunities expected to influence the lupus market growth during the forecast period.
Lupus is a systemic autoimmune illness that produces widespread inflammation. The immune system targets healthy cells and tissues in lupus patients, causing damage to numerous regions of the body, including the skin, joints, kidneys, heart, lungs, blood vessels, and brain. During the projection period, factors such as rising lupus prevalence, ongoing medical developments in the treatment of systemic lupus erythematous, and increased research and development efforts are projected to fuel lupus market growth. The Lupus Foundation of America estimates that 1.5 million Americans have lupus, with 16,000 new cases recorded each year in the Americas. Despite the drivers, market growth may be hampered by obstacles such as rigorous government regulation and rising lupus drug prices over the assessment period.
In the lupus market nowadays, there are a huge number of enterprises. The creation of new products and the introduction of new products are involving the major market players. For example, GlaxoSmithKline got FDA approval in July 2021 for a novel Benlysta self-injectable formulation for the treatment of adult patients with systemic lupus erythematous.
Lupus Market segment analysis:
The Global Lupus Market is segmented into Technique, Product, and End-user.
Based on technique, the systemic lupus erythematous segment held largest share of 12.41% in 2024, owing to treatment can help you manage your symptoms, avoid flare-ups, and avoid other lupus-related health issues. No steroidal anti-inflammatory drugs (NSAIDs) are the most widely utilised medications to treat lupus (NSAIDs). Pain, edoema, and fever associated with lupus can be treated with over-the-counter NSAIDs such as naproxen sodium (Aleve) and ibuprofen (Advil, Motrin IB, and others).
Based on product, the biologics segment is currently leading the market, with a CAGR of 7.2% expected during the forecast period. The introduction of new biologics with improved efficacy, such as Benlysta and Rituximab, is projected to drive category growth. Benlysta is used to treat moderate SLE (Systemic Lupus Erythematous), however its safety and efficiency in severe Lupus are still unknown. Immunosuppressants and corticosteroids, on the other hand, have a long list of negative effects. Rituximab, on the other hand, has none.
Regional Insight:
North America’s lupus market was valued at US$ 12 Mn. in 2024 and is expected to reach a value of US$ 89 Mn. by 2032, with a CAGR of 50% during the forecast period. This is owing to the availability of reimbursement, growing demand for better treatment options, rising prevalence of lupus, government initiatives for lupus. Moreover, the developed healthcare infrastructure and accessibility to biologics are likely to contribute to the lupus market growth in the region. The U.S. has the highest number of people diagnosed from LN in 2022, followed by the U.K. and Japan. The prevalence of lupus nephritis in the AAPC SLE patient population is much higher than in Caucasians. Therefore, it represents a large and well-defined market opportunity with very little competition and is expected to be worth US$ 89 billion by 2022 at a CAGR of 29 %.
The objective of the report is to present a comprehensive analysis of the global Lupus market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the global Lupus market dynamics, structure by analyzing the market segments and projects the global market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global market make the report investor’s guide.
Lupus Market Scope: Inquire before buying
| Lupus Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2024 | Forecast Period: | 2025-2032 |
| Historical Data: | 2019 to 2024 | Market Size in 2024: | USD 3.01 Bn. |
| Forecast Period 2025 to 2032 CAGR: | 12.41% | Market Size in 2032: | USD 7.68 Bn. |
| Segments Covered: | by Technique | Systemic Lupus Erythematosus Cutaneous Lupus Erythematosus Drug-Induced Lupus Erythematosus Neonatal Lupus |
|
| by Product | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Antimalarial Drugs Corticosteroids Immunosuppressants Biologics Others |
||
| by End User | Hospital & Clinics Diagnostic Laboratories Other |
||
Lupus Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Lupus Market, Key Players:
1. Aurinia Pharmaceuticals
2. Bristol-Myers Squibb
3. Cadila Healthcare
4. GlaxoSmithKline plc
5. Mylan N.V.
6. F. Hoffmann-La
7. Pfizer, Inc.
8. Sanofi
9. Lycera Corporation
10. Merck KGaA
11. Eli Lily
12. ImmuPharma LLC
13. Anthera Pharmaceuticals
14. Lycera
15. Sandoz International GmbH
16. Novartis AG,
17. Bayer AG
18. Trinity Biotech
Frequently Asked Questions:
1. Which region has the largest share in Global Lupus Market?
Ans: North America region holds the highest share in 2024.
2. What was the Global Lupus Market size in 2024?
Ans: The Global Lupus Market size was USD 3.01 Billion in 2024.
3. What segments are covered in Global Lupus market?
Ans: Global Lupus Market is segmented into technique, product, end-user and region.
4. Who are the key players in Global Lupus market?
Ans: The important key players in the Global Lupus Market are – Aurinia Pharmaceuticals, Bristol-Myers Squibb, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La , Pfizer, Inc., Sanofi, Lycera Corporation, Merck KGaA, Eli Lily , ImmuPharma LLC, Anthera Pharmaceuticals.
5. What is the study period of this market?
Ans: The Global Lupus Market is studied from 2024 to 2032.